Phacilitate Leaders Forum

Interview with Dr Sven Kili

Interview with Dr Sven Kili

One of the big gene therapy success stories of 2016 so far has been the approval of GlaxoSmithKline’s Strimvelis by the European Commission, to treat patients with ADA-SCID.

Ahead of Phacilitate’s Cell & Gene Therapy Europe next week, we had the pleasure of talking with Dr Sven Kili, VP and Head of Cell & Gene Therapy Development at GlaxoSmithKline about the next steps now that Strimvelis has been approved, the changing model of orphan drug designation, and how the commercial supply chain strategy for Strimvelis is taking shape.


 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd